Immune system targeting by biodegradable nanoparticles for cancer vaccines

Journal of Controlled Release

Volumn 168, Issue 2, 2013, Pages 179-199

  Silva, Joana M ^a,b   Videira, Mafalda ^a   Gaspar, Rogério ^a   Préat, Véronique ^b   Florindo, Helena F ^a  

^a UNIVERSITY OF LISBON   (Portugal)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Active targeting; Adjuvants; Cancer vaccines; Immunotherapy; Nanoparticles

Indexed keywords

ACTIVE TARGETING; ADJUVANTS; BIODEGRADABLE ALIPHATIC POLYESTERS; BIODEGRADABLE NANOPARTICLE; CANCER VACCINE; IMMUNOTHERAPY; PARTICULATE DELIVERY SYSTEMS; POLY(LACTIC-CO-GLYCOLIC ACID);

ANTIGENS; COPOLYMERS; IMMUNE SYSTEM; NANOPARTICLES; TUMORS;

VACCINES;

CANCER VACCINE; COPOLYMER; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 6; MACROGOL; NANOCARRIER; NANOPARTICLE; POLY(3 HYDROXYBUTYRIC ACID); POLYCAPROLACTONE; POLYESTER; POLYETHYLENE; POLYGLACTIN; POLYGLYCOLIC ACID; POLYLACTIC ACID; POLYLACTIDE; SUBUNIT VACCINE; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ADJUVANT THERAPY; ANTIGEN PRESENTATION; APOPTOSIS; BIODEGRADABILITY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER STEM CELL; CELL DEATH; CELL MATURATION; CELL SURFACE; CHEMICAL STRUCTURE; CIRCULATION TIME; CROSS PRESENTATION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; DOWN REGULATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; ELECTROPHORETIC MOBILITY; ENDOCYTOSIS; ENDOPLASMIC RETICULUM; GLYCOSYLATION; HUMAN; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; INTRACELLULAR SIGNALING; IONIC STRENGTH; MASS SPECTROMETRY; NANOEMULSION; NATURAL KILLER CELL; NATURAL KILLER T CELL; NONHUMAN; PHAGOCYTOSIS; PINOCYTOSIS; POINT MUTATION; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; SURFACE CHARGE; T LYMPHOCYTE; TH1 CELL; TUMOR MICROENVIRONMENT; ZETA POTENTIAL;

ANIMALS; CANCER VACCINES; DENDRITIC CELLS; HUMANS; LIGANDS; NANOPARTICLES; TOLL-LIKE RECEPTORS;

EID: 84877945468     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2013.03.010     Document Type: Review

References (297)

1. J. Begley, and A. Ribas Targeted therapies to improve tumor immunotherapy Clin. Cancer Res. 14 14 2008 4385 4391
2. P.M. Dimberu, and R.M. Leonhardt Cancer immunotherapy takes a multi-faceted approach to kick the immune system into gear Yale J. Biol. Med. 84 4 2011 371 380
3. D.E. Speiser, and P. Romero Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity Semin. Immunol. 22 3 2010 144 154
4. H. Benlalam, N. Labarrière, B. Linard, L. Derré, E. Diez, M.C. Pandolfino, M. Bonneville, and F. Jotereau Comprehensive analysis of the frequency of recognition of melanoma associated antigen (MAA) by CD8 melanoma infiltrating lymphocytes (TIL): implications for immunotherapy Eur. J. Immunol. 31 7 2001 2007 2015
5. R. Barnetson, and G. Halliday Regression in skin tumours: a common phenomenon Australas. J. Dermatol. 38 Suppl. 1 1997 S63 S65
6. U.N. Rao, S.J. Lee, W. Luo, M.C. Mihm, and J.M. Kirkwood Presence of tumor-infiltrating lymphocytes and a dominant nodule within primary melanoma are prognostic factors for relapse-free survival of patients with thick (t4) primary melanoma: pathologic analysis of the e1690 and e1694 intergroup trials Am. J. Clin. Pathol. 133 4 2010 646 653
7. H. Yaziji, and A.M. Gown Immunohistochemical markers of melanocytic tumors Int. J. Surg. Pathol. 11 1 2003 11 15
8. C. Nicholas, and G.B. Lesinski Immunomodulatory cytokines as therapeutic agents for melanoma Immunotherapy 3 5 2011 673 690
9. L. Vujanovic, and L.H. Butterfield Melanoma cancer vaccines and anti-tumor T cell responses J. Cell. Biochem. 102 2 2007 301 310
10. R. Duncan, and R. Gaspar Nanomedicine(s) under the microscope Mol. Pharm. 8 6 2011 2101 2141
11. E. Schlosser, M. Mueller, S. Fischer, S. Basta, D.H. Busch, B. Gander, and M. Groettrup TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses Vaccine 26 13 2008 1626 1637
12. R.A. Henderson, S. Mossman, N. Nairn, and M.A. Cheever Cancer vaccines and immunotherapies: emerging perspectives Vaccine 23 17-18 2005 2359 2362
13. P.H. Verardi, A. Titong, and C.J. Hagen A vaccinia virus renaissance: new vaccine and immunotherapeutic uses after smallpox eradication Hum. Vaccin. Immunother. 8 7 2012 961 970
14. P. Ravanfar, A. Satyaprakash, R. Creed, and N. Mendoza Existing antiviral vaccines Dermatol. Ther. 22 2 2009 110 128
15. S. Riedel Edward Jenner and the history of smallpox and vaccination Proc. (Bayl. Univ. Med. Cent.) 18 1 2005 21 25
16. S.A. Plotkin History of Vaccine Development S.A. Plotkin, 2011 Springer New York New York, NY
17. T.A. Waldmann Immunotherapy: past, present and future Nat. Med. 9 3 2003 269 277
18. J.I. Lundin, and H. Checkoway Endotoxin and cancer Environ. Health Perspect. 117 9 2009 1344 1350
19. E. Vacchelli, I. Martins, A. Eggermont, W.H. Fridman, J. Galon, C. Sautès-Fridman, E. Tartour, L. Zitvogel, G. Kroemer, and L. Galluzzi Trial watch: peptide vaccines in cancer therapy Oncoimmunology 1 9 2012 1557 1576
20. P. Malyala, D.T. O'Hagan, and M. Singh Enhancing the therapeutic efficacy of CpG oligonucleotides using biodegradable microparticles Adv. Drug Deliv. Rev. 61 3 2009 218 225
21. Y. Krishnamachari, S.M. Geary, C.D. Lemke, and A.K. Salem Nanoparticle delivery systems in cancer vaccines Pharm. Res. 28 2 2011 215 236
22. L. Matera The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer Cancer Treat. Rev. 36 2 2010 131 141
23. P. Van der Bruggen, C. Traversari, P. Chomez, C. Lurquin, E. De Plaen, B.J. Van den Eynde, A. Knuth, and T. Boon A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma J. Immunol. 178 5 2007 2617 2621
24. L. Novellino, C. Castelli, and G. Parmiani A listing of human tumor antigens recognized by T cells: March 2004 update Cancer Immunol. Immunother. 54 3 2005 187 207
25. L. Zhao, Z. Liu, and D. Fan Overview of mimotopes and related strategies in tumor vaccine development Expert Rev. Vaccines 7 10 2008 1547 1555
26. G. Parmiani, C. Castelli, P. Dalerba, R. Mortarini, L. Rivoltini, F.M. Marincola, and A. Anichini Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J. Natl. Cancer Inst. 94 11 2002 805 818
27. J.P. Higgins, M.B. Bernstein, and J.W. Hodge Enhancing immune responses to tumor-associated antigens Cancer Biol. Ther. 8 15 2009 1440 1449
28. S. Pejawar-Gaddy, Y. Rajawat, Z. Hilioti, J. Xue, D.F. Gaddy, O.J. Finn, R.P. Viscidi, and I. Bossis Generation of a tumor vaccine candidate based on conjugation of a MUC1 peptide to polyionic papillomavirus virus-like particles Cancer Immunol. Immunother. 59 11 2010 1685 1696
29. P. Dalerba, R.W. Cho, and M.F. Clarke Cancer stem cells: models and concepts Annu. Rev. Med. 58 2007 267 284
30. M.H. Andersen, I.M. Svane, J.C. Becker, and P.T. Straten The universal character of the tumor-associated antigen survivin Clin. Cancer Res. 13 20 2007 5991 5994
31. Z.-L. Liao, X.-D. Tang, M.-H. Lü, Y.-Y. Wu, Y.-L. Cao, D.-C. Fang, S.-M. Yang, and H. Guo Antitumor effect of new multiple antigen peptide based on HLA-A0201-restricted CTL epitopes of human telomerase reverse transcriptase (hTERT) Cancer Sci. 103 11 2012 1920 1928
32. G. Parmiani, V. Russo, A. Marrari, G. Cutolo, C. Casati, L. Pilla, C. Maccalli, L. Rivoltini, and C. Castelli Universal and stemness-related tumor antigens: potential use in cancer immunotherapy Clin. Cancer Res. 13 19 2007 5675 5679
33. A. Anichini, A. Molla, R. Mortarini, G. Tragni, I. Bersani, M. Di Nicola, A.M. Gianni, S. Pilotti, R. Dunbar, V. Cerundolo, and G. Parmiani An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions J. Exp. Med. 190 5 1999 651 667
34. Y. Maeda, N. Hida, F. Niiya, K. Katagiri, M. Harada, H. Yamana, T. Kamura, M. Takahashi, Y. Sato, S. Todo, and K. Itoh Detection of peptide-specific CTL-precursors in peripheral blood lymphocytes of cancer patients Br. J. Cancer 87 7 2002 796 804
35. M. Noguchi, T. Sasada, and K. Itoh Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccine Cancer Immunol. Immunother. 2012 10.1007/s00262-012-1379-1
36. M. Sensi, and A. Anichini Unique tumor antigens: evidence for immune control of genome integrity and immunogenic targets for T cell-mediated patient-specific immunotherapy Clin. Cancer Res. 12 17 2006 5023 5032
37. K. Itoh, and A. Yamada Personalized peptide vaccines: a new therapeutic modality for cancer Cancer Sci. 97 10 2006 970 976
38. G.A. Poland, R.B. Kennedy, and I.G. Ovsyannikova Vaccinomics and personalized vaccinology: is science leading us toward a new path of directed vaccine development and discovery? G.F. Rall, PLoS Pathog. 7 12 2011 e1002344
39. S.A. Rosenberg, J.C. Yang, and N.P. Restifo Cancer immunotherapy: moving beyond current vaccines Nat. Med. 10 9 2004 909 915
40. J. Crespo, H. Sun, T.H. Welling, Z. Tian, and W. Zou T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment Curr. Opin. Immunol. 25 2013 1 8
41. T.F. Gajewski, Y. Meng, C. Blank, I. Brown, A. Kacha, J. Kline, and H. Harlin Immune resistance orchestrated by the tumor microenvironment Immunol. Rev. 213 2006 131 145
42. W.J. Lesterhuis, J.B. Haanen, and C.J. Punt Cancer immunotherapy - revisited Nat. Rev. Drug Discov. 10 8 2011 591 600
43. M. Aleksic, N. Liddy, P.E. Molloy, N. Pumphrey, A. Vuidepot, K.-M. Chang, and B.K. Jakobsen Different affinity windows for virus and cancer-specific T-cell receptors: implications for therapeutic strategies Eur. J. Immunol. 42 12 2012 3174 3179
44. M. Hebeisen, L. Baitsch, D. Presotto, P. Baumgaertner, P. Romero, O. Michielin, D.E. Speiser, and N. Rufer SHP-1 phosphatase activity counteracts increased T cell receptor affinity J. Clin. Invest. 123 3 2013 1044 1056
45. M.Y. Mapara, and M. Sykes Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance J. Clin. Oncol. 22 6 2004 1136 1151
46. S. Ray, A. Chhabra, S. Mehrotra, N.G. Chakraborty, A. Ribas, J. Economou, and B. Mukherji Obstacles to and opportunities for more effective peptide-based therapeutic immunization in human melanoma Clin. Dermatol. 27 6 2009 603 613
47. H. Prado-Garcia, S. Romero-Garcia, D. Aguilar-Cazares, M. Meneses-Flores, and J.S. Lopez-Gonzalez Tumor-induced CD8 + T-cell dysfunction in lung cancer patients Clin. Dev. Immunol. 2012 2012 741741
48. S. Mehrotra, A. Chhabra, S. Chattopadhyay, D.I. Dorsky, N.G. Chakraborty, and B. Mukherji Rescuing melanoma epitope-specific cytolytic T lymphocytes from activation-induced cell death, by SP600125, an inhibitor of JNK: implications in cancer immunotherapy J. Immunol. 173 10 2004 6017 6024
49. S. Mumprecht, C. Schürch, J. Schwaller, M. Solenthaler, and A.F. Ochsenbein Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression Blood 114 8 2009 1528 1536
50. C. Zielinski, S. Knapp, C. Mascaux, and F. Hirsch Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer Ann. Oncol. 2013 10.1093/annonc/mds647 (Electronic publication ahead of print)
51. D. Lindau, P. Gielen, M. Kroesen, P. Wesseling, and G.J. Adema The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells Immunology 138 2 2013 105 115
52. R. Morita, Y. Hirohashi, and N. Sato Depletion of Tregs in vivo: a promising approach to enhance antitumor immunity without autoimmunity Immunotherapy 4 11 2012 1103 1105
53. T.L. Whiteside Disarming suppressor cells to improve immunotherapy Cancer Immunol. Immunother. 61 2 2012 283 288
54. R. Kennedy, and E. Celis Multiple roles for CD4 + T cells in anti tumor immune responses Immunol. Rev. 222 1 2008 129 144
55. H.M. Zarour, J.M. Kirkwood, L.S. Kierstead, W. Herr, V. Brusic, C.L. Slingluff, J. Sidney, A. Sette, and W.J. Storkus Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells Proc. Natl. Acad. Sci. U. S. A. 97 1 2000 400 405
56. S.P. Kerkar, L. Sanchez-Perez, S. Yang, Z. Borman, P. Muranski, Y. Ji, D. Chinnasamy, A.D.M. Kaiser, C. Hinrichs, C.A. Klebanoff, C. Scott, L. Gattinoni, R.A. Morgan, S.A. Rosenberg, and N.P. Restifo Genetic engineering of murine CD8 + and CD4 + T cells for preclinical adoptive immunotherapy studies J. Immunother. 34 4 2011 343 352
57. H. Shen, A.L. Ackerman, V. Cody, A. Giodini, E.R. Hinson, P. Cresswell, R.L. Edelson, W.M. Saltzman, and D.J. Hanlon Enhanced and prolonged cross presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles Immunology 117 1 2006 78 88
58. J. Bukur, S. Jasinski, and B. Seliger The role of classical and non-classical HLA class I antigens in human tumors Semin. Cancer Biol. 22 4 2012 350 358
59. J. Bubeník MHC class I down-regulation: tumour escape from immune surveillance? (Review) Int. J. Oncol. 25 2 2004 487 491
60. G.A. Rabinovich, D. Gabrilovich, and E.M. Sotomayor Immunosuppressive strategies that are mediated by tumor cells Annu. Rev. Immunol. 25 2007 267 296
61. J. Liu, S. Liao, B. Diop-Frimpong, W. Chen, S. Goel, K. Naxerova, M. Ancukiewicz, Y. Boucher, R.K. Jain, and L. Xu TGF-β blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma Proc. Natl. Acad. Sci. U. S. A. 109 41 2012 16618 16623
62. S. Nawrocki, and A. Mackiewicz Genetically modified tumour vaccines - where we are today Cancer Treat. Rev. 25 1 1999 29 46
63. M.L. Taddei, E. Giannoni, G. Comito, and P. Chiarugi Microenvironment and tumor cell plasticity: an easy way out Cancer Lett. 2013 10.1016/j.canlet.2013. 01.042
64. Y. Huang, S. Shah, and L. Qiao Tumor resistance to CD8 + T cell-based therapeutic vaccination Arch. Immunol. Ther. Exp. (Warsz.) 55 4 2007 205 217
65. J.D. Ahlers, and I.M. Belyakov Memories that last forever: strategies for optimizing vaccine T-cell memory Blood 115 9 2010 1678 1679
66. T. Nishimura, K. Iwakabe, M. Sekimoto, Y. Ohmi, T. Yahata, M. Nakui, T. Sato, S. Habu, H. Tashiro, M. Sato, and A. Ohta Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo J. Exp. Med. 190 5 1999 617 627
67. Y. Becker Molecular immunological approaches to biotherapy of human cancers - a review, hypothesis and implications Anticancer Res. 26 2A 2006 1113 1134
68. E. Gilboa The promise of cancer vaccines Nat. Rev. Cancer 4 5 2004 401 411
69. M. Rossi, and J.W. Young Human dendritic cells: potent antigen-presenting cells at the crossroads of innate and adaptive immunity J. Immunol. 175 3 2005 1373 1381
70. M. Merad, and M.G. Manz Dendritic cell homeostasis Blood 113 15 2009 3418 3427
71. O. Takeuchi, and S. Akira Pattern recognition receptors and inflammation Cell 140 6 2010 805 820
72. T.F. Gajewski, M.B. Fuertes, and S.-R. Woo Innate immune sensing of cancer: clues from an identified role for type I IFNs Cancer Immunol. Immunother. 61 8 2012 1343 1347
73. L. Delamarre, M. Pack, H. Chang, I. Mellman, and E.S. Trombetta Differential lysosomal proteolysis in antigen-presenting cells determines antigen fate Science 307 5715 2005 1630 1634
74. N. Kadowaki Dendritic cells: a conductor of T cell differentiation Allergol. Int. 56 3 2007 193 199
75. A. Martín-Fontecha, S. Sebastiani, U.E. Höpken, M. Uguccioni, M. Lipp, A. Lanzavecchia, and F. Sallusto Regulation of dendritic cell migration to the draining lymph node J. Exp. Med. 198 4 2003 615 621
76. A.K. Palucka, H. Ueno, J. Fay, and J. Banchereau Dendritic cells: a critical player in cancer therapy? J. Immunother. 31 9 2008 793 805
77. H. Hillaireau, and P. Couvreur Nanocarriers' entry into the cell: relevance to drug delivery Cell. Mol. Life Sci. 66 17 2009 2873 2896
78. J.A. Hubbell, S.N. Thomas, and M.A. Swartz Materials engineering for immunomodulation Nature 462 7272 2009 449 460
79. M. Raghavan, N. Del Cid, S.M. Rizvi, and L.R. Peters MHC class I assembly: out and about Trends Immunol. 29 9 2008 436 443
80. I. Hwang, and D.L. Ki Receptor-mediated T cell absorption of antigen presenting cell-derived molecules Front. Biosci. 16 2011 411 421
81. S. Takeuchi, and M. Furue Dendritic cells: ontogeny Allergol. Int. 56 3 2007 215 223
82. P. Muranski, and N.P. Restifo Adoptive immunotherapy of cancer using CD4 + T cells Curr. Opin. Immunol. 21 2 2009 200 208
83. B.A. Cobb, and D.L. Kasper Coming of age: carbohydrates and immunity Eur. J. Immunol. 35 2 2005 352 356
84. G. De Libero, and L. Mori How the immune system detects lipid antigens Prog. Lipid Res. 49 2 2010 120 127
85. F. Facciotti, M. Cavallari, C. Angénieux, L.F. Garcia-Alles, F. Signorino-Gelo, L. Angman, M. Gilleron, J. Prandi, G. Puzo, L. Panza, C. Xia, P.G. Wang, P. Dellabona, G. Casorati, S.A. Porcelli, H. Salle, L. Mori, and G. De Libero Fine tuning by human CD1e of lipid-specific immune responses Proc. Natl. Acad. Sci. U. S. A. 108 34 2011 14228 14233
86. G. De Libero, A. Collmann, and L. Mori The cellular and biochemical rules of lipid antigen presentation Eur. J. Immunol. 39 10 2009 2648 2656
87. D.I. Godfrey, D.G. Pellicci, O. Patel, L. Kjer-Nielsen, J. McCluskey, and J. Rossjohn Antigen recognition by CD1d-restricted NKT T cell receptors Semin. Immunol. 22 2 2010 61 67
88. A. Schiefner, and I.A. Wilson Presentation of lipid antigens by CD1 glycoproteins Curr. Pharm. Des. 15 28 2009 3311 3317
89. S.-I. Fujii, K. Shimizu, C. Smith, L. Bonifaz, and R.M. Steinman Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein J. Exp. Med. 198 2 2003 267 279
90. S. Hakomori Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism Cancer Res. 56 23 1996 5309 5318
91. J. Heimburg-Molinaro, M. Lum, G. Vijay, M. Jain, A. Almogren, and K. Rittenhouse-Olson Cancer vaccines and carbohydrate epitopes Vaccine 29 48 2011 8802 8826
92. A. Pashov, B. Monzavi-Karbassi, and T. Kieber-Emmons Glycan mediated immune responses to tumor cells Hum. Vaccin. 7 2011 156 165 (Suppl.)
93. B. Monzavi-Karbassi, A. Pashov, F. Jousheghany, C. Artaud, and T. Kieber-Emmons Evaluating strategies to enhance the anti-tumor immune response to a carbohydrate mimetic peptide vaccine Int. J. Mol. Med. 17 6 2006 1045 1052
94. M.A. Cheever, J.P. Allison, A.S. Ferris, O.J. Finn, B.M. Hastings, T.T. Hecht, I. Mellman, S.A. Prindiville, J.L. Viner, L.M. Weiner, and L.M. Matrisian The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research Clin. Cancer Res. 15 17 2009 5323 5337
95. A.M. Vlad, J.C. Kettel, N.M. Alajez, C.A. Carlos, and O.J. Finn MUC1 immunobiology: from discovery to clinical applications Adv. Immunol. 82 2004 249 293
96. N. Gaidzik, U. Westerlind, and H. Kunz The development of synthetic antitumour vaccines from mucin glycopeptide antigens Chem. Soc. Rev. 2013 10.1039/C3CS35470A (Electronic publication ahead of print)
97. A. Kaiser, N. Gaidzik, U. Westerlind, D. Kowalczyk, A. Hobel, E. Schmitt, and H. Kunz A synthetic vaccine consisting of a tumor-associated sialyl-T(N)-MUC1 tandem-repeat glycopeptide and tetanus toxoid: induction of a strong and highly selective immune response Angew. Chem. Int. Ed Engl. 48 41 2009 7551 7555
98. H. Cai, Z.-H. Huang, L. Shi, Z.-Y. Sun, Y.-F. Zhao, H. Kunz, and Y.M. Li Variation of the glycosylation pattern in MUC1 glycopeptide BSA vaccines and its influence on the immune response Angew. Chem. Int. Ed Engl. 51 7 2012 1719 1723
99. Z. Mazorra, C. Mesa, A. Fernández, and L.E. Fernández Immunization with a GM3 ganglioside nanoparticulated vaccine confers an effector CD8(+) T cells-mediated protection against melanoma B16 challenge Cancer Immunol. Immunother. 57 12 2008 1771 1780
100. H. Kumar, T. Kawai, and S. Akira Pathogen recognition in the innate immune response Biochem. J. 420 1 2009 1 16
101. B. Beutler Microbe sensing, positive feedback loops, and the pathogenesis of inflammatory diseases Immunol. Rev. 227 1 2009 248 263
102. D. Wesch, C. Peters, H.-H. Oberg, K. Pietschmann, and D. Kabelitz Modulation of γδ T cell responses by TLR ligands Cell. Mol. Life Sci. 68 14 2011 2357 2370
103. G. Schreibelt, J. Tel, K.H. Sliepen, D. Benitez-Ribas, C.G. Figdor, G.J. Adema, and I.J. de Vries Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy Cancer Immunol. Immunother. 59 10 2010 1573 1582
104. S.S. Diebold Activation of dendritic cells by Toll-like receptors and C-type lectins Handb. Exp. Pharmacol. 188 2009 3 30
105. K. Takeda, T. Kaisho, and S. Akira Toll-like receptors Annu. Rev. Immunol. 21 1 2003 335 376
106. G. Gautier, M. Humbert, F. Deauvieau, M. Scuiller, J. Hiscott, E.M. Bates, G. Trinchieri, C. Caux, and P. Garrone A type I interferon autocrine-paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells J. Exp. Med. 201 9 2005 1435 1446
107. C.A. Sariol, M.I. Martínez, F. Rivera, I.V. Rodríguez, P. Pantoja, K. Abel, T. Arana, L. Giavedoni, V. Hodara, L.J. White, Y.I. Angleró, L.J. Montaner, and E.N. Kraiselburd Decreased dengue replication and an increased anti-viral humoral response with the use of combined Toll-like receptor 3 and 7/8 agonists in macaques PLoS One 6 4 2011 e19323
108. M.S. Duthie, H.P. Windish, C.B. Fox, and S.G. Reed Use of defined TLR ligands as adjuvants within human vaccines Immunol. Rev. 239 1 2011 178 196
109. G. Liu, L. Zhang, and Y. Zhao Modulation of immune responses through direct activation of Toll like receptors to T cells Clin. Exp. Immunol. 160 2 2010 168 175
110. A.M. Avalos, E. Latz, B. Mousseau, S.R. Christensen, M.J. Shlomchik, F. Lund, and A. Marshak-Rothstein Differential cytokine production and bystander activation of autoreactive B cells in response to CpG-A and CpG-B oligonucleotides J. Immunol. 183 10 2009 6262 6268
111. J. Vollmer, R. Weeratna, P. Payette, M. Jurk, C. Schetter, M. Laucht, T. Wader, S. Tluk, M. Liu, H.L. Davis, and A.M. Krieg Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities Eur. J. Immunol. 34 1 2004 251 262
112. S. Agrawal, and E. Kandimalla Synthetic agonists of Toll-like receptors 7, 8 and 9 Biochem. Soc. Trans. 35 6 2007 1461 1467
113. T. Barata, I. Teo, S. Lalwani, E. Simanek, M. Zloh, and S. Shaunak Computational design principles for bioactive dendrimer based constructs as antagonists of the TLR4-MD-2-LPS complex Biomaterials 32 33 2011 8702 8711
114. T.S. Barata, I. Teo, S. Brocchini, M. Zloh, and S. Shaunak Partially glycosylated dendrimers block MD-2 and prevent TLR4-MD-2-LPS complex mediated cytokine responses PLoS Comput. Biol. 7 6 2011 e1002095
115. + T-cell responses in melanoma patients Eur. J. Immunol. 42 11 Novembro de 2012 3049 3061
116. B.K. Link, Z.K. Ballas, D. Weisdorf, J.E. Wooldridge, A.D. Bossler, M. Shannon, W.L. Rasmussen, A.M. Krieg, and G.J. Weiner Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma J. Immunother. 29 5 2006 558 568
117. A. Carpentier, F. Laigle-Donadey, S. Zohar, L. Capelle, A. Behin, A. Tibi, N. Martin-Duverneuil, M. Sanson, L. Lacomblez, S. Taillibert, L. Puybasset, R. Van Effenterre, J.Y. Delattre, and A.F. Carpentier Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma Neuro Oncol. 8 1 2006 60 66
118. C. Manegold, D. Gravenor, D. Woytowitz, J. Mezger, V. Hirsh, G. Albert, M. Al-Adhami, D. Readett, A.M. Krieg, and C.G. Leichman Randomized phase II trial of a Toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer J. Clin. Oncol. 26 24 2008 3979 3986
119. A.L. Engel, G.E. Holt, and H. Lu The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system Expert Rev. Clin. Pharmacol. 4 2 2011 275 289
120. R. Brunner, E. Jensen-Jarolim, and I. Pali-Schöll The ABC of clinical and experimental adjuvants - a brief overview Immunol. Lett. 128 1 2010 29 35
121. N. Petrovsky, and J.C. Aguilar Vaccine adjuvants: current state and future trends Immunol. Cell Biol. 82 5 2004 488 496
122. I.F. Hermans, J.D. Silk, U. Gileadi, M. Salio, B. Mathew, G. Ritter, R. Schmidt, A.L. Harris, L. Old, and V. Cerundolo NKT cells enhance CD4 + and CD8 + T cell responses to soluble antigen in vivo through direct interaction with dendritic cells J. Immunol. 171 10 2003 5140 5147
123. S. Kusmartsev, and D.I. Gabrilovich Role of immature myeloid cells in mechanisms of immune evasion in cancer Cancer Immunol. Immunother. 55 3 2006 237 245
124. Q. Gao, S.-J. Qiu, J. Fan, J. Zhou, X.-Y. Wang, Y.-S. Xiao, Y. Xu, Y.W. Li, and Z.Y. Tang Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection J. Clin. Oncol. 25 18 2007 2586 2593
125. Y. Zhang, F. Luo, Y. Cai, N. Liu, L. Wang, D. Xu, and Y. Chu TLR1/TLR2 agonist induces tumor regression by reciprocal modulation of effector and regulatory T cells J. Immunol. 186 4 2011 1963 1969
126. H.-H. Oberg, M. Juricke, D. Kabelitz, and D. Wesch Regulation of T cell activation by TLR ligands Eur. J. Cell Biol. 90 6-7 2011 582 592
127. T. Warger, P. Osterloh, G. Rechtsteiner, M. Fassbender, V. Heib, B. Schmid, E. Schmitt, H. Schild, and M.P. Radsak Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo Blood 108 2 2006 544 550
128. Y. Yang, C.T. Huang, X. Huang, and D.M. Pardoll Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance Nat. Immunol. 5 5 2004 508 515
129. I. Caramalho, T. Lopes-Carvalho, D. Ostler, S. Zelenay, M. Haury, and J. Demengeot Regulatory T cells selectively express Toll-like receptors and are activated by lipopolysaccharide J. Exp. Med. 197 4 2003 403 411
130. Q. Chen, T.S. Davidson, E.N. Huter, and E.M. Shevach Engagement of TLR2 does not reverse the suppressor function of mouse regulatory T cells, but promotes their survival J. Immunol. 183 7 2009 4458 4466
131. A. Olivier, A. Sainz-Perez, H. Dong, T. Sparwasser, L. Majlessi, and C. Leclerc The adjuvant effect of TLR agonists on CD4(+) effector T cells is under the indirect control of regulatory T cells Eur. J. Immunol. 41 8 2011 2303 2313
132. C. Tanchot, M. Terme, H. Pere, T. Tran, N. Benhamouda, M. Strioga, C. Banissi, L. Galluzzi, G. Kroemer, and E. Tartour Tumor-infiltrating regulatory T cells: phenotype, role, mechanism of expansion in situ and clinical significance Cancer Microenviron. 2012 10.1007/s12307-012-0122-y (Electronic publication ahead of print)
133. C. Zoglmeier, H. Bauer, D. Nörenberg, G. Wedekind, P. Bittner, N. Sandholzer, M. Rapp, D. Anz, S. Endres, and C. Bourquin CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice Clin. Cancer Res. 17 7 2011 1765 1775
134. R. Arens, and S.P. Schoenberger Plasticity in programming of effector and memory CD8 + T cell formation Immunol. Rev. 235 1 2010 190 205
135. M.F. Bachmann, and G.T. Jennings Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns Nat. Rev. Immunol. 10 11 2010 787 796
136. S.L. Demento, S.C. Eisenbarth, H.G. Foellmer, C. Platt, M.J. Caplan, W.M. Saltzman, I. Mellman, M. Ledizet, E. Fikrig, R.A. Flavell, and T.M. Fahmy Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy Vaccine 27 23 2009 3013 3021
137. M. Diwan, M. Tafaghodi, and J. Samuel Enhancement of immune responses by co-delivery of a CpG oligodeoxynucleotide and tetanus toxoid in biodegradable nanospheres J. Control. Release 85 1-3 2002 247 262
138. H.F. Florindo, S. Pandit, L. Gonçalves, M. Videira, O. Alpar, and A.J. Almeida Antibody and cytokine-associated immune responses to S. equi antigens entrapped in PLA nanospheres Biomaterials 30 28 2009 5161 5169
139. C. Clawson, C.-T. Huang, D. Futalan, D.M. Seible, R. Saenz, M. Larsson, W. Ma, B. Minev, F. Zhang, M. Ozkan, C. Ozkan, S. Esener, and D. Messmer Delivery of a peptide via poly (d, l-lactic-co-glycolic) acid nanoparticles enhances its dendritic cell-stimulatory capacity Nanomedicine 6 5 2010 651 661
140. E. Macho Fernandez, J. Chang, J. Fontaine, E. Bialecki, F. Rodriguez, E. Werkmeister, V. Krieger, C. Ehreti, B. Heurtault, S. Fournel, B. Frisch, D. Betbeder, C. Faveeuw, and F. Trottein Activation of invariant Natural Killer T lymphocytes in response to the α-galactosylceramide analogue KRN7000 encapsulated in PLGA-based nanoparticles and microparticles Int. J. Pharm. 423 1 2012 45 54
141. J. Panyam, and V. Labhasetwar Biodegradable nanoparticles for drug and gene delivery to cells and tissue Adv. Drug Deliv. Rev. 55 3 2003 329 347
142. J. Damm, F. Wiegand, L.M. Harden, R. Gerstberger, C. Rummel, and J. Roth Fever, sickness behavior, and expression of inflammatory genes in the hypothalamus after systemic and localized subcutaneous stimulation of rats with the Toll-like receptor 7 agonist imiquimod Neuroscience 201 2012 166 183
143. P.J. Tacken, I.S. Zeelenberg, L.J. Cruz, M.A. van Hout-Kuijer, G. van de Glind, R.G. Fokkink, A.J. Lambeck, and C.G. Figdor Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity Blood 118 26 2011 6836 6844
144. D.N. Nguyen, K.P. Mahon, G. Chikh, P. Kim, H. Chung, A.P. Vicari, K.T. Love, M. Goldberg, S. Chen, A.M. Krieg, J. Chen, R. Langer, and D.G. Anderson Lipid-derived nanoparticles for immunostimulatory RNA adjuvant delivery Proc. Natl. Acad. Sci. U. S. A. 109 14 2012 E797 E803
145. R.A. Jain, C.T. Rhodes, A.M. Railkar, A.W. Malick, and N.H. Shah Controlled release of drugs from injectable in situ formed biodegradable PLGA microspheres: effect of various formulation variables Eur. J. Pharm. Biopharm. 50 2 2000 257 262
146. R.P.M. Sutmuller, M.E. Morgan, M.G. Netea, O. Grauer, and G.J. Adema Toll-like receptors on regulatory T cells: expanding immune regulation Trends Immunol. 27 8 2006 387 393
147. K. Park Mechanism of cross-presentation of microencapsulated antigen J. Control. Release 151 3 2011 219
148. J. Panyam, W. Zhou, S. Prabha, S.K. Sahoo, and V. Labhase Rapid endo-lysosomal escape of poly (dl-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery FASEB J. 16 10 2002 1217 1226
149. A. Gamvrellis, D. Leong, J.C. Hanley, S.D. Xiang, P. Mottram, and M. Plebanski Vaccines that facilitate antigen entry into dendritic cells Immunol. Cell Biol. 82 5 2004 506 516
150. Y. Krishnamachari, and A.K. Salem Innovative strategies for co-delivering antigens and CpG oligonucleotides Adv. Drug Deliv. Rev. 61 3 2009 205 217
151. S. Hamdy, O. Molavi, Z. Ma, A. Haddadi, A. Alshamsan, Z. Gobti, S. Elhasi, J. Samuel, and A. Lavasanifar Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8 + T cell-mediated anti-tumor immunity Vaccine 26 39 2008 5046 5057
152. Y.R. Lee, Y.H. Lee, S.A. Im, I.H. Yang, G.W. Ahn, K. Kim, and C.K. Lee Biodegradable nanoparticles containing TLR3 or TLR9 agonists together with antigen enhance MHC-restricted presentation of the antigen Arch. Pharm. Res. 33 11 2010 1859 1866
153. G.W. Stone, S. Barzee, V. Snarsky, C. Santucci, B. Tran, R. Langer, G.T. Zugates, D.G. Anderson, and R.S. Kornbluth Nanoparticle-delivered multimeric soluble CD40L DNA combined with Toll-like receptor agonists as a treatment for melanoma PLoS One 4 10 2009 e7334
154. B. Slütter, and W. Jiskoot Dual role of CpG as immune modulator and physical crosslinker in ovalbumin loaded N-trimethyl chitosan (TMC) nanoparticles for nasal vaccination J. Control. Release 148 1 2010 117 121
155. S.P. Kasturi, I. Skountzou, R.A. Albrecht, D. Koutsonanos, T. Hua, H. Nakaya, R. Ravindran, S. Stewart, M. Alam, M. Kwissa, F. Villinger, N. Murthy, J. Steel, J. Jacob, R.J. Hogan, A. García-Sastre, R. Compans, and B. Pulendran Programming the magnitude and persistence of antibody responses with innate immunity Nature 470 7335 2011 543 547
156. D. Tross, L. Petrenko, S. Klaschik, Q. Zhu, and D.M. Klinman Global changes in gene expression and synergistic interactions induced by TLR9 and TLR3 Mol. Immunol. 46 13 2009 2557 2564
157. A. Sapin, E. Garcion, A. Clavreul, F. Lagarce, J.P. Benoit, and P. Menei Development of new polymer-based particulate systems for anti-glioma vaccination Int. J. Pharm. 309 1-2 17 de Fevereiro de 2006 1 5
158. C. Foged, B. Brodin, S. Frokjaer, and A. Sundblad Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model Int. J. Pharm. 298 2 2005 315 322
159. K. Cho, X. Wang, S. Nie, Z.G. Chen, and D.M. Shin Therapeutic nanoparticles for drug delivery in cancer Clin. Cancer Res. 14 5 2008 1310 1316
160. S.D. Xiang, A. Scholzen, G. Minigo, C. David, V. Apostolopoulos, P.L. Mottram, and M. Plebanski Pathogen recognition and development of particulate vaccines: does size matter? Methods 40 1 2006 1 9
161. D.K. Cureton, R.H. Massol, S. Saffarian, T.L. Kirchhausen, and S.P.J. Whelan Vesicular stomatitis virus enters cells through vesicles incompletely coated with clathrin that depend upon actin for internalization PLoS Pathog. 5 4 2009 e1000394
162. D.K. Cureton, R.H. Massol, S.P.J. Whelan, and T. Kirchhausen The length of vesicular stomatitis virus particles dictates a need for actin assembly during clathrin-dependent endocytosis J.A.T. Young, PLoS Pathog. 6 9 2010 e1001127
163. K.T. Thurn, E.M. Brown, A. Wu, S. Vogt, B. Lai, J. Maser, T. Paunesku, and G.E. Woloschak Nanoparticles for applications in cellular imaging Nanoscale Res. Lett. 2 9 2007 430 441
164. J. Liu, H. Bauer, J. Callahan, P. Kopecková, H. Pan, and J. Kopecek Endocytic uptake of a large array of HPMA copolymers: elucidation into
165. Z.G. Yue, W. Wei, P.P. Lv, H. Yue, L.Y. Wang, Z.G. Su, and G.H. Ma Surface charge affects cellular uptake and intracellular trafficking of chitosan-based nanoparticles Biomacromolecules 12 7 2011 2440 2446
166. T.L. Doane, C.-H. Chuang, R.J. Hill, and C. Burda Nanoparticle ζ-potentials Acc. Chem. Res. 45 3 2012 317 326
167. S. Venkataraman, J.L. Hedrick, Z.Y. Ong, C. Yang, P.L. Ee, P.T. Hammond, and Y.Y. Yang The effects of polymeric nanostructure shape on drug delivery Adv. Drug Deliv. Rev. 63 14-15 2011 1228 1246
168. L. Florez, C. Herrmann, J.M. Cramer, C.P. Hauser, K. Koynov, K. Landfester, D. Crespy, and V. Mailänder How shape influences uptake: interactions of anisotropic polymer nanoparticles and human mesenchymal stem cells Small 8 14 2012 2222 2230
169. D.E. Owens, and N.A. Peppas Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles Int. J. Pharm. 307 1 2006 93 102
170. I. Lynch, T. Cedervall, M. Lundqvist, C. Cabaleiro-Lago, S. Linse, and K.A. Dawson The nanoparticle-protein complex as a biological entity; a complex fluids and surface science challenge for the 21st century Adv. Colloid Interface Sci. 134-135 2007 167 174
171. P. Aggarwal, J.B. Hall, C.B. McLeland, M.A. Dobrovolskaia, and S.E. McNeil Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy Adv. Drug Deliv. Rev. 61 6 2009 428 437
172. F. Alexis, E. Pridgen, L.K. Molnar, and O.C. Farokhzad Factors affecting the clearance and biodistribution of polymeric nanoparticles Mol. Pharm. 5 4 2008 505 515
173. M. Lundqvist, J. Stigler, G. Elia, I. Lynch, T. Cedervall, and K.A. Dawson Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts Proc. Natl. Acad. Sci. U. S. A. 105 38 2008 14265 14270
174. S. Tenzer, D. Docter, S. Rosfa, A. Wlodarski, J. Kuharev, A. Rekik, S.K. Knauer, C. Bantz, T. Nawroth, C. bier, J. Sirirattanapan, W. Mann, L. Treuel, R. Zellner, M. Maskos, H. Schild, and R.H. Stauber Nanoparticle size is a critical physicochemical determinant of the human blood plasma corona: a comprehensive quantitative proteomic analysis ACS Nano 5 9 2011 7155 7157
175. C. Kelly, C. Jefferies, and S.A. Cryan Targeted liposomal drug delivery to monocytes and macrophages J. Drug Deliv. 2011 2011 727241
176. D.J. Bharali, V. Pradhan, G. Elkin, W. Qi, A. Hutson, S.A. Mousa, and Y. Thanavala Novel nanoparticles for the delivery of recombinant hepatitis B vaccine Nanomedicine 4 4 2008 311 317
177. H. Freichels, V. Pourcelle, R. Auzély-Velty, J. Marchand-Brynaert, and C. Jérôme Synthesis of poly(lactide-co-glycolide-co-ε- caprolactone)-graft-mannosylated poly(ethylene oxide) copolymers by combination of «clip» and «click» chemistries Biomacromolecules 13 3 2012 760 768
178. J.H. Van den Berg, K. Oosterhuis, W.E. Hennink, G. Storm, L.J. Van der Aa, J.F. Engbersen, J.B. Haanenc, J.H. Beijnena, T.N. Schumacherc, and B. Nuijena Shielding the cationic charge of nanoparticle-formulated dermal DNA vaccines is essential for antigen expression and immunogenicity J. Control. Release 141 2 2010 234 240
179. E. Fernandez-Megia, R. Novoa-Carballal, E. Quiñoá, and R. Riguera Conjugation of bioactive ligands to PEG-grafted chitosan at the distal end of PEG Biomacromolecules 8 3 2007 833 842
180. Y. Van Kooyk C-type lectins on dendritic cells: key modulators for the induction of immune responses Biochem. Soc. Trans. 36 Pt 6 2008 1478 1481
181. W.W.J. Unger, and Y. Van Kooyk «Dressed for success» C-type lectin receptors for the delivery of glyco-vaccines to dendritic cells Curr. Opin. Immunol. 23 1 2010 131 137
182. U. Gazi, and L. Martinez-Pomares Influence of the mannose receptor in host immune responses Immunobiology 214 7 2009 554 561
183. S. Burgdorf, A. Kautz, V. Böhnert, P.A. Knolle, and C. Kurts Distinct pathways of antigen uptake and intracellular routing in CD4 and CD8 T cell activation Science 316 5824 2007 612 616
184. S. Hamdy, A. Haddadi, A. Shayeganpour, J. Samuel, and A. Lavasanifar Activation of antigen-specific T cell-responses by mannan-decorated PLGA nanoparticles Pharm. Res. 28 9 2011 2288 3301
185. N. Brandhonneur, F. Chevanne, V. Vié, B. Frisch, R. Primault, M.F. Le Potier, and P. Le Corre Specific and non-specific phagocytosis of ligand-grafted PLGA microspheres by macrophages Eur. J. Pharm. Sci. 36 4-5 2009 474 485
186. G.K. Saraogi, B. Sharma, B. Joshi, P. Gupta, U.D. Gupta, N.K. Jain, and G.P. Agrawal Mannosylated gelatin nanoparticles bearing isoniazid for effective management of tuberculosis J. Drug Target. 19 3 2011 219 227
187. S. Espuelas, C. Thumann, B. Heurtault, F. Schuber, and B. Frisch Influence of ligand valency on the targeting of immature human dendritic cells by mannosylated liposomes Bioconjug. Chem. 19 12 2008 2385 2393
188. L.Z. He, A. Crocker, J. Lee, J. Mendoza-Ramirez, X.T. Wang, L.A. Vitale, T. O'Neill, C. Petromilli, H.F. Zhang, J. Lopez, D. Rohrer, T. Keler, and R. Clynes Antigenic targeting of the human mannose receptor induces tumor immunity J. Immunol. 178 10 2007 6259 6267
189. V. Ramakrishna, J.F. Treml, L. Vitale, J.E. Connolly, T. O'Neill, P.A. Smith, C.L. Jones, L.Z. He, J. Goldstein, P.K. Wallace, T. Keler, and M.J. Endres Mannose receptor targeting of tumor antigen pmel17 to human dendritic cells directs anti-melanoma T cell responses via multiple HLA molecules J. Immunol. 172 5 2004 2845 2852
190. V. Flacher, C.H. Tripp, P. Stoitzner, B. Haid, S. Ebner, B. Del Frari, F. Koch, C.G. Park, R.M. Steinman, J. Idoyaga, and N. Romani Epidermal Langerhans cells rapidly capture and present antigens from C-type lectin-targeting antibodies deposited in the dermis J. Invest. Dermatol. 130 3 2009 755 762
191. F. Danhier, E. Ansorena, J.M. Silva, R. Coco, A. Le Breton, and V. Préat PLGA-based nanoparticles: an overview of biomedical applications J. Control. Release 161 2 2012 505 522
192. K.A. Athanasiou, G.G. Niederauer, and C. Agrawal Sterilization, toxicity, biocompatibility and clinical applications of polylactic acid/polyglycolic acid copolymers Biomaterials 17 2 1996 93 102
193. A.-C. Albertsson, and I.K. Varma Recent developments in ring opening polymerization of lactones for biomedical applications Biomacromolecules 4 6 2003 1466 1486
194. S.H. Hyon, K. Jamshidi, and Y. Ikada Synthesis of polylactides with different molecular weights Biomaterials 18 22 1997 1503 1508
195. C.M. Thomas Stereocontrolled ring-opening polymerization of cyclic esters: synthesis of new polyester microstructures Chem. Soc. Rev. 39 1 2010 165 173
196. S. Kobayashi, H. Uyama, and S. Kimura Enzymatic polymerization Chem. Rev. 101 12 2001 3793 3818
197. J.S. Dordick Enzymatic and chemoenzymatic approaches to polymer synthesis Trends Biotechnol. 10 8 1992 287 290
198. O. Dechy-Cabaret, B. Martin-Vaca, and D. Bourissou Controlled ring-opening polymerization of lactide and glycolide Chem. Rev. 104 12 2004 6147 6176
199. R. Platel, L. Hodgson, and C. Williams Biocompatible initiators for lactide polymerization Polym. Rev. 48 1 Janeiro de 2008 11 63
200. H.R. Kricheldorf Syntheses and application of polylactides Chemosphere 43 1 2001 49 54
201. M. Labet, and W. Thielemans Synthesis of polycaprolactone: a review Chem. Soc. Rev. 38 12 2009 3484 3504
202. H. Huatan, J.H. Collett, D. Attwood, and C. Booth Preparation and characterization of poly(epsilon-caprolactone) polymer blends for the delivery of proteins Biomaterials 16 17 1995 1297 1303
203. H. Abe, and Y. Doi Structural effects on enzymatic degradabilities for poly[(R)-3-hydroxybutyric acid] and its copolymers Int. J. Biol. Macromol. 25 1-3 1999 185 192
204. S.J. Peter, M.J. Yaszemski, L.J. Suggs, R.G. Payne, R. Langer, W.C. Hayes, M.R. Unroe, I.B. Alemany, P.S. Engel, and A.G. Mikos Characterization of partially saturated poly(propylene fumarate) for orthopaedic application J. Biomater. Sci. Polym. Ed. 8 11 1997 893 904
205. J. Liu, P. Chen, J. Li, S.-H. Jiang, Z.-Q. Jiang, and Q. Gu Synthesis of poly(ethylene adipate-co-l-lactic acid) copolymers via ring opening polymerization Polym. Bull. 66 2 2011 187 197
206. H. Qian, A.R. Wohl, J.T. Crow, C.W. Macosko, and T.R. Hoye A strategy for control of «random» copolymerization of lactide and glycolide: application to synthesis of PEG-b-PLGA block polymers having narrow dispersity Macromolecules 44 18 2011 7132 7140
207. C.W. Lee, R. Urakawa, and Y. Kimura Copolymerization of γ-valerolactone and β-butyrolactone Eur. Polym. J. 34 1 1998 117 122
208. S. Malberg, A. Hoglund, and A.-C. Albertsson Macromolecular design of aliphatic polyesters with maintained mechanical properties and a rapid, customized degradation profile Biomacromolecules 12 6 2011 2382 2388
209. M.A. Woodruff, and D.W. Hutmacher The return of a forgotten polymer - polycaprolactone in the 21st century Prog. Polym. Sci. 35 10 2010 1217 1256
210. M. Ryner, and A.-C. Albertsson Resorbable and highly elastic block copolymers from 1,5-dioxepan-2-one and l-lactide with controlled tensile properties and hydrophilicity Biomacromolecules 3 3 2002 601 608
211. X. Pang, X. Zhuang, Z. Tang, and X. Chen Polylactic acid (PLA): research, development and industrialization Biotechnology 5 11 2010 1125 1136
212. G.T. Köse, H. Kenar, N. Hasirci, and V. Hasirci Macroporous poly(3-hydroxybutyrate-co-3-hydroxyvalerate) matrices for bone tissue engineering Biomaterials 24 11 2003 1949 1958
213. K.S. Jack, S. Velayudhan, P. Luckman, M. Trau, L. Grøndahl, and J. Cooper-White The fabrication and characterization of biodegradable HA/PHBV nanoparticle-polymer composite scaffolds Acta Biomater. 5 7 2009 2657 2667
214. G. Khang, S.W. Kim, J.C. Cho, J.M. Rhee, S.C. Yoon, and H.B. Lee Preparation and characterization of poly(3-hydroxybutyrate-co-3-hydroxyvalerate) microspheres for the sustained release of 5-fluorouracil Biomed. Mater. Eng. 11 2 2001 89 103
215. J.B.E. Mendes, M.K. Riekes, V.M. De Oliveira, M.D. Michel, H.K. Stulzer, N.M. Khalil, S.F. Zawadzki, R.M. Mainardes, and P.V. Farago PHBV/PCL microparticles for controlled release of resveratrol: physicochemical characterization, antioxidant potential, and effect on hemolysis of human erythrocytes Scientific World Journal 2012 2012 542937
216. J.M. Lü, X. Wang, C. Marin-Muller, H. Wang, P.H. Lin, Q. Yao, and C. Chen Current advances in research and clinical applications of PLGA-based nanotechnology Expert Rev. Mol. Diagn. 9 4 2009 325 341
217. R.A. Jain The manufacturing techniques of various drug loaded biodegradable poly (lactide-co-glycolide)(PLGA) devices Biomaterials 21 23 2000 2475 2490
218. R.G. Soderquist, E.M. Sloane, L.C. Loram, J.A. Harrison, E.C. Dengler, S.M. Johnson, L.D. Amer, C.S. Young, M.T. Lewis, S. Poole, M.G. Frank, L.R. Watkins, E.D. Milligan, and M.J. Mahoney Release of plasmid DNA-encoding IL-10 from PLGA microparticles facilitates long-term reversal of neuropathic pain following a single intrathecal administration Pharm. Res. 27 5 2010 841 854
219. D. Cun, D.K. Jensen, M.J. Maltesen, M. Bunker, P. Whiteside, D. Scurr, C. Foged, and H.M. Nielsen High loading efficiency and sustained release of siRNA encapsulated in PLGA nanoparticles: quality by design optimization and characterization Eur. J. Pharm. Biopharm. 77 1 2010 26 35
220. C. Solbrig, J. Saucier-Sawyer, V. Cody, W. Saltzman, and D. Hanlon Polymer nanoparticles for immunotherapy from encapsulated tumor-associated antigens and whole tumor cells Mol. Pharm. 4 1 2007 47 57
221. M. Diwan, P. Elamanchili, H. Lane, A. Gainer, and J. Samuel Biodegradable nanoparticle mediated antigen delivery to human cord blood derived dendritic cells for induction of primary T cell responses J. Drug Target. 11 8-10 2003 495 507
222. S. Prasad, V. Cody, J.K. Saucier-Sawyer, W.M. Saltzman, C.T. Sasaki, R.L. Edelson, M.A. Birchall, and D.J. Hanlon Polymer nanoparticles containing tumor lysates as antigen delivery vehicles for dendritic cell-based antitumor immunotherapy Nanomedicine 7 1 2011 1 10
223. C.M. Thomas, A. Rawat, L.J. Hope-Weeks, and F. Ahsan Aerosolized PLA and PLGA nanoparticles enhance humoral, mucosal and cytokine responses to hepatitis B vaccine Mol. Pharm. 27 2010 905 919
224. J. Tian, and J. Yu Cell biology of antigen processing in vitro and in vivo Fish Shellfish Immunol. 30 1 2010 109 117
225. W. Jiang, R.K. Gupta, M.C. Deshpande, and S.P. Schwendeman Biodegradable poly (lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens Adv. Drug Deliv. Rev. 57 3 2005 391 410
226. M. Garinot, V. Fiévez, V. Pourcelle, F. Stoffelbach, A. Des Rieux, L. Plapied, I. Theate, H. Freichels, C. Jérôme, J. Marchand-Brynaert, Y.J. Schneider, and V. Préat PEGylated PLGA-based nanoparticles targeting M cells for oral vaccination J. Control. Release 120 3 2007 195 204
227. H.F. Florindo, S. Pandit, L.M.D. Gonçalves, H.O. Alpar, and A.J. Almeida New approach on the development of a mucosal vaccine against strangles: systemic and mucosal immune responses in a mouse model Vaccine 27 8 2009 1230 1241
228. M. Diwan, P. Elamanchili, M. Cao, and J. Samuel Dose sparing of CpG oligodeoxynucleotide vaccine adjuvants by nanoparticle delivery Curr. Drug Deliv. 1 4 2004 405 412
229. V. Sinha, K. Bansal, R. Kaushik, R. Kumria, and A. Trehan Poly-[epsilon]-caprolactone microspheres and nanospheres: an overview Int. J. Pharm. 278 1 2004 1 23
230. F.S. Bates, M.A. Hillmyer, T.P. Lodge, C.M. Bates, K.T. Delaney, and G.H. Fredrickson Multiblock polymers: panacea or Pandora's box? Science 336 6080 2012 434 440
231. T. Kissel, Y. Li, and F. Unger ABA-triblock copolymers from biodegradable polyester A-blocks and hydrophilic poly(ethylene oxide) B-blocks as a candidate for in situ forming hydrogel delivery systems for proteins Adv. Drug Deliv. Rev. 54 1 2002 99 134
232. X.-B. Xiong, A. Falamarzian, S.M. Garg, and A. Lavasanifar Engineering of amphiphilic block copolymers for polymeric micellar drug and gene delivery J. Control. Release 155 2 2011 248 261
233. M.L. Adams, A. Lavasanifar, and G.S. Kwon Amphiphilic block copolymers for drug delivery J. Pharm. Sci. 92 7 2003 1343 1355
234. Y. Yang, Y. Kuang, Y. Liu, W. Li, Z. Jiang, L. Xiao, and M. Li Immunogenicity of multiple-epitope antigen gene of HCV carried by novel biodegradable polymers Comp. Immunol. Microbiol. Infect. Dis. 34 1 2011 65 72
235. M. Barz, F.K. Wolf, F. Canal, K. Koynov, M.J. Vicent, H. Frey, and R. Zentel Synthesis, characterization and preliminary biological evaluation of P(HPMA)-b-P(LLA) copolymers: a new type of functional biocompatible block copolymer Macromol. Rapid Commun. 31 17 2010 1492 1500
236. J. Shao, J. Sun, X. Bian, Y. Cui, G. Li, and X. Chen Investigation of poly(lactide) stereocomplexes: 3-armed poly(l-lactide) blended with linear and 3-armed enantiomers J. Phys. Chem. B 116 33 2012 9983 9991
237. M. Barz, A. Armiñán, F. Canal, F. Wolf, K. Koynov, H. Frey, R. Zentel, and M.J. Vicent P(HPMA)-block-P(LA) copolymers in paclitaxel formulations: polylactide stereochemistry controls micellization, cellular uptake kinetics, intracellular localization and drug efficiency J. Control. Release 163 1 2012 63 74
238. F. Ahmed, R.I. Pakunlu, G. Srinivas, A. Brannan, F. Bates, M.L. Klein, T. Minko, and D.E. Discher Shrinkage of a rapidly growing tumor by drug-loaded polymersomes: pH-triggered release through copolymer degradation Mol. Pharm. 3 3 2006 340 350
239. A. Blencowe, J.F. Tan, T.K. Goh, and G.G. Qiao Core cross-linked star polymers via controlled radical polymerisation Polymer 50 1 2009 5 32
240. D.J.A. Cameron, and M.P. Shaver Aliphatic polyester polymer stars: synthesis, properties and applications in biomedicine and nanotechnology Chem. Soc. Rev. 40 3 2011 1761 1776
241. J. Jansen, M.P. Tibbe, G. Mihov, J. Feijen, and D.W. Grijpma Photo-crosslinked networks prepared from fumaric acid monoethyl ester-functionalized poly(d, l-lactic acid) oligomers and N-vinyl-2-pyrrolidone for the controlled and sustained release of proteins Acta Biomater. 8 10 2012 3652 3659
242. J. Zotzmann, A. Alteheld, M. Behl, and A. Lendlein Amorphous phase-segregated copoly(ether)esterurethane thermoset networks with oligo(propylene glycol) and oligo[(rac-lactide)-co-glycolide] segments: synthesis and characterization J. Mater. Sci. Mater. Med. 20 9 2009 1815 1824
243. K. Nagahama, T. Saito, T. Ouchi, and Y. Ohya Biodegradable nano-aggregates of star-shaped 8-arm PEG -PLLA block co-polymers for encapsulation of water-soluble macromolecules J. Biomater. Sci. Polym. Ed. 22 1-3 2011 407 416 (10)
244. M. Vert, S.M. Li, G. Spenlehauer, and P. Guerin Bioresorbability and biocompatibility of aliphatic polyesters J. Mater. Sci. Mater. Med. 3 6 1992 432 446
245. N.A. Weir, F.J. Buchanan, J.F. Orr, and G.R. Dickson Degradation of poly-l-lactide. Part 1: in vitro and in vivo physiological temperature degradation Proc. Inst. Mech. Eng. H 218 5 2004 307 319
246. A. Göpferich, and J. Tessmar Polyanhydride degradation and erosion Adv. Drug Deliv. Rev. 54 7 2002 911 931
247. S. Li Hydrolytic degradation characteristics of aliphatic polyesters derived from lactic and glycolic acids J. Biomed. Mater. Res. 48 3 1999 342 353
248. S.C. Loo, C.P. Ooi, S.H. Wee, and Y.C. Boey Effect of isothermal annealing on the hydrolytic degradation rate of poly (lactide-co-glycolide) (PLGA) Biomaterials 26 16 2005 2827 2833
249. A.N. Ford Versypt, D.W. Pack, and R.D. Braatz Mathematical modeling of drug delivery from autocatalytically degradable PLGA microspheres - a review J. Control. Release 165 1 2013 29 37
250. M.L. Houchin, and E.M. Topp Chemical degradation of peptides and proteins in PLGA: a review of reactions and mechanisms J. Pharm. Sci. 97 7 2008 2395 2404
251. R.C. Mundargi, V.R. Babu, V. Rangaswamy, P. Patel, and T.M. Aminabhavi Nano/micro technologies for delivering macromolecular therapeutics using poly (d, l-lactide-co-glycolide) and its derivatives J. Control. Release 125 3 2008 193 209
252. Y. Waeckerle-Men, and M. Groettrup PLGA microspheres for improved antigen delivery to dendritic cells as cellular vaccines Adv. Drug Deliv. Rev. 57 3 2005 475 482
253. S.K. Mallapragada, and B. Narasimhan Immunomodulatory biomaterials Int. J. Pharm. 364 2 2008 265 271
254. S.U. Frick, N. Bacher, G. Baier, V. Mailänder, K. Landfester, and K. Steinbrink Functionalized polystyrene nanoparticles trigger human dendritic cell maturation resulting in enhanced CD4 + T cell activation Macromol. Biosci. 12 12 2012 1637 1647
255. R. Nicolete, D.F. dos Santos, and L.H. Faccioli The uptake of PLGA micro or nanoparticles by macrophages provokes distinct in vitro inflammatory response Int. Immunopharmacol. 11 10 2011 1557 1563
256. S. Fischer, E. Uetz-von Allmen, Y. Waeckerle-Men, M. Groettrup, H.P. Merkle, and B. Gander The preservation of phenotype and functionality of dendritic cells upon phagocytosis of polyelectrolyte-coated PLGA microparticles Biomaterials 28 6 2007 994 1004
257. B. Nilsson, K.N. Ekdahl, T.E. Mollnes, and J.D. Lambris The role of complement in biomaterial-induced inflammation Mol. Immunol. 44 1-3 2007 82 94
258. S.M. Moghimi, A.J. Andersen, D. Ahmadvand, P.P. Wibroe, T.L. Andresen, and A.C. Hunter Material properties in complement activation Adv. Drug Deliv. Rev. 63 12 2011 1000 1007
259. V.C. Mosqueira, P. Legrand, A. Gulik, O. Bourdon, R. Gref, D. Labarre, and G. Barratt Relationship between complement activation, cellular uptake and surface physicochemical aspects of novel PEG-modified nanocapsules Biomaterials 22 22 2001 2967 2979
260. Q. He, J. Liu, X. Sun, and Z.R. Zhang Preparation and characteristics of DNA-nanoparticles targeting to hepatocarcinoma cells World J. Gastroenterol. 10 5 2004 660 663
261. S. Malathi, and S. Balasubramanian Synthesis of biodegradable polymeric nanoparticles and their controlled drug delivery for tuberculosis J. Biomed. Nanotechnol. 7 1 2011 150 151
262. A. Des Rieux, V. Fievez, M. Garinot, Y.J. Schneider, and V. Préat Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach J. Control. Release 116 1 2006 1 27
263. N. Anton, J.P. Benoit, and P. Saulnier Design and production of nanoparticles formulated from nano-emulsion templates - a review J. Control. Release 128 3 2008 185 199
264. M. Estevan, J.M. Irache, M.J. Grillo, J.M. Blasco, and C. Gamazo Encapsulation of antigenic extracts of Salmonella enterica serovar: Abortusovis into polymeric systems and efficacy as vaccines in mice Vet. Microbiol. 118 1-2 2006 124 132
265. H. Florindo, S. Pandit, L. Goncalves, H. Alpar, and A. Almeida S. equi antigens adsorbed onto surface modified poly-epsilon-caprolactone microspheres induce humoral and cellular specific immune responses Vaccine 26 33 2008 4168 4177
266. S.K. Sahoo, J. Panyam, S. Prabha, and V. Labhasetwar Residual polyvinyl alcohol associated with poly (d, l-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake J. Control. Release 82 1 2002 105 114
267. T. Storni, T. Kundig, G. Senti, and P. Johansen Immunity in response to particulate antigen-delivery systems Adv. Drug Deliv. Rev. 57 3 2005 333 355
268. T.E. Rajapaksa, K.M. Bennett, M. Hamer, C. Lytle, V.G.J. Rodgers, and D.D. Lo Intranasal M cell uptake of nanoparticles is independently influenced by targeting ligands and buffer ionic strength J. Biol. Chem. 285 31 2010 23739 23746
269. J.U. Menon, S. Kona, A.S. Wadajkar, F. Desai, A. Vadla, and K.T. Nguyen Effects of surfactants on the properties of PLGA nanoparticles J. Biomed. Mater. Res. A 100A 8 2012 1998 2005
270. A.M. Cerdeira, I.A. Werner, M. Mazzotti, and B. Gander Simultaneous quantification of polymeric and surface active stabilizers of nanosuspensions by using near-infrared spectroscopy Drug Dev. Ind. Pharm. 38 11 2012 1360 1370
271. Y.-C. Wang, Y.-T. Wu, H.-Y. Huang, and C.-S. Yang Surfactant-free formulation of poly(lactic/glycolic) acid nanoparticles encapsulating functional polypeptide: a technical note AAPS PharmSciTech 10 4 2009 1263 1267
272. M. Zanetti, and G. Franchini T cell memory and protective immunity by vaccination: is more better? Trends Immunol. 27 11 2006 511 517
273. S. Moffatt, and R.J. Cristiano Uptake characteristics of NGR-coupled stealth PEI/pDNA nanoparticles loaded with PLGA-PEG-PLGA tri-block copolymer for targeted delivery to human monocyte-derived dendritic cells Int. J. Pharm. 321 1-2 2006 143 154
274. X. Shan, Y. Yuan, C. Liu, X. Tao, Y. Sheng, and F. Xu Influence of PEG chain on the complement activation suppression and longevity in vivo prolongation of the PCL biomedical nanoparticles Biomed. Microdevices 11 6 2009 1187 1194
275. N. Romani, M. Thurnher, J. Idoyaga, R.M. Steinman, and V. Flacher Targeting of antigens to skin dendritic cells: possibilities to enhance vaccine efficacy Immunol. Cell Biol. 88 4 2010 424 430
276. M. Peiser, J. Koeck, C.J. Kirschning, B. Wittig, and R. Wanner Human Langerhans cells selectively activated via Toll-like receptor 2 agonists acquire migratory and CD4 + T cell stimulatory capacity J. Leukoc. Biol. 83 5 2008 1118 1127
277. D.H. Kaplan In vivo function of Langerhans cells and dermal dendritic cells Trends Immunol. 31 12 2010 446 451
278. F.O. Nestle, P. Di Meglio, J.Z. Qin, and B.J. Nickoloff Skin immune sentinels in health and disease Nat. Rev. Immunol. 9 10 2009 679 691
279. B.S. Kim, F. Miyagawa, Y.H. Cho, C.L. Bennett, B.E. Clausen, and S.I. Katz Keratinocytes function as accessory cells for presentation of endogenous antigen expressed in the epidermis J. Invest. Dermatol. 129 12 2009 2805 2817
280. K. Sato, and S. Fujita Dendritic cells: nature and classification Allergol. Int. 56 3 2007 183 191
281. C. Winzler, P. Rovere, M. Rescigno, F. Granucci, G. Penna, L. Adorini, V.S. Zimmermann, J. Davoust, and P. Ricciardi-Castagnoli Maturation stages of mouse dendritic cells in growth factor-dependent long-term cultures J. Exp. Med. 185 2 1997 317 328
282. M. Adamina, R. Rosenthal, W.P. Weber, D.M. Frey, C.T. Viehl, M. Bolli, R.W. Huegli, A.L. Jacob, M. Heberer, D. Oertli, W. Marti, G.C. Spagnoli, and P. Zajac Intranodal immunization with a vaccinia virus encoding multiple antigenic epitopes and costimulatory molecules in metastatic melanoma Mol. Ther. 18 3 2009 651 659
283. K.A. Smith, B.L. Meisenburg, V.L. Tam, R.R. Pagarigan, R. Wong, D.K. Joea, L. Lantzy, M.A. Carrillo, T.M. Gross, U.M. Malyankar, C.S. Chiang, D.M. Da Silva, T.M. Kündig, W.M. Kast, Z. Qiu, and A. Bot Lymph node-targeted immunotherapy mediates potent immunity resulting in regression of isolated or metastatic human papillomavirus-transformed tumors Clin. Cancer Res. 15 19 2009 6167 6176
284. S.T. Reddy, A.J. van der Vlies, E. Simeoni, V. Angeli, G.J. Randolph, C.P. O'Neil, L.K. Lee, M.A. Swartz, and J.A. Hubbell Exploiting lymphatic transport and complement activation in nanoparticle vaccines Nat. Biotechnol. 25 10 2007 1159 1164
285. K.J. Maloy, I. Erdmann, V. Basch, S. Sierro, T.A. Kramps, R.M. Zinkernagel, S. Oehen, and T.M. Kündig Intralymphatic immunization enhances DNA vaccination Proc. Natl. Acad. Sci. U. S. A. 98 6 2001 3299 3303
286. S. Kreiter, A. Selmi, M. Diken, M. Koslowski, C.M. Britten, C. Huber, Ö. Türeci, and U. Sahin Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity Cancer Res. 70 22 2010 9031 9040
287. C.D. Platt, J.K. Ma, C. Chalouni, M. Ebersold, H. Bou-Reslan, R.A. Carano, I. Mellman, and L. Delamarre Mature dendritic cells use endocytic receptors to capture and present antigens Proc. Natl. Acad. Sci. U. S. A. 107 9 2010 4287 4292
288. N.S. Wilson, D. El-Sukkari, G.T. Belz, C.M. Smith, R.J. Steptoe, W.R. Heath, K. Shortman, and J.A. Villadangos Most lymphoid organ dendritic cell types are phenotypically and functionally immature Blood 102 6 2003 2187 2194
289. J.A. Villadangos, and W.R. Heath Life cycle, migration and antigen presenting functions of spleen and lymph node dendritic cells: limitations of the Langerhans cells paradigm Semin. Immunol. 17 4 2005 262 272
290. S.T. Tagawa, P. Lee, J. Snively, W. Boswell, S. Ounpraseuth, S. Lee, B. Hickingbottom, J. Smith, D. Johnson, and J.S. Weber Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with stage IV melanoma Cancer 98 1 2003 144 154
291. R. Gaspar Regulatory issues surrounding nanomedicines: setting the scene for the next generation of nanopharmaceuticals Nanomedicine (Lond.) 2 2 2007 143 147
292. R. Gaspar, and R. Duncan Polymeric carriers: preclinical safety and the regulatory implications for design and development of polymer therapeutics Adv. Drug Deliv. Rev. 61 13 2009 1220 1231
293. D. Bowman, A. Maynard, and R. Gaspar Chapter 14: therapeutic products: regulating drugs and medical devices International Handbook on Regulating Nanotechnologies 2010 Edward Elgar Pub Northampton, MA 291 320
294. European Medicines Agency C Vaccines Working Party - «Workplan for 2013» http://www.ema.europa.eu/docs/en-GB/document-library/Work-programme/ 2010/02/WC500073590.pdf 2013
295. European Medicines Agency C Note for guidance on the clinical evaluation of vaccines [Internet] EMEA/CHMP/VWP/164653/2005 2005 (http://www.ema.europa.eu/ docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003875.pdf)
296. European Medicines Agency C Guideline on adjuvants in vaccines for human use [Internet] EMEA/CHMP/VEG/134716/2004 2005 (http://www.ema.europa.eu/docs/en- GB/document-library/Scientific-guideline/2009/09/WC500003809.pdf)
297. Food and Drugs Administration O of C, Tissue and Gene Therapies. CLINICAL CONSIDERATIONS FOR THERAPEUTIC CANCER VACCINES [Internet]. FDA's Center for Biologics Evaluation and Research, 2011. (http://www.fda.gov/downloads/ biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/ vaccines/ucm278673.pdf).